Azitra, Inc. to Present New Data at Three Upcoming Scientific Conferences in May 2024

April 18, 2024 8:15 PM EDT

- ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD, May 7-11, 2024
- SID (Society of Investigative Dermatology) Dallas, TX, May 15-18, 2024
- ASCO (American Society of Clinical Oncology) Chicago, IL, May 31 – June 4, 2024

BRAHMS, Conn.--(BUSINESS WIRE)--Apr. 18, 2024--Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced it will be presenting promising new preclinical data from its platform built (or optimized) to discover treatments for serious skin diseases at three upcoming scientific and medical conferences:

ASGCT (American Society of Gene and Cell Therapy) Baltimore, MD

- Title: Engineered Staphylococcus Epidermidis as a Protein Delivery System for Treating Skin Diseases
- Format: Oral presentation
- Date: May 10th, 4:15pm – 4:35pm EDT

SID (Society of Investigative Dermatology) Dallas, TX

- Title: Cutaneous delivery of LEKTI via an engineered strain of Staphylococcus epidermidis for the treatment of Netherton syndrome
- Format: Oral presentation
- Date: Friday May 17th, 2024 9:30AM – 11:00AM CDT

ASCO (American Society of Clinical Oncology) Chicago, IL

- Title: Preclinical development of ATR04-484, an auxotrophic strain of Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity
- Format: Poster presentation
- Date: Friday May 17th, 2024 4:00 – 6:00 PM EDT

About Azitra, Inc.

Azitra, Inc. is an early-stage clinical biopharmaceutical company focused on developing innovative therapies for precision dermatology using engineered proteins and topical live biotherapeutic products. The Company has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts, and helps screen the Company’s library of strains for drug-like molecules. The Company’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis, or S. epidermidis, which the Company considers to be an optimal live therapeutic candidate species for engineering of dermatologic therapies. For more information, please visit https://azitrainc.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “可能发生,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, without limitation, statements regarding the expected timing of the presentation of data from the Phase 1b study of ATR04, the filing of an IND application, and the presentation of data from our Phase 1b for ATR04, the IND filing for ATR01, the timing of having a signed license agreement with Bayer, and statements about our clinical and pre-clinical programs, and corporate and clinical/pre-clinical strategies.

Forward-looking statements in this press release are based on current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, that we may fail to successfully complete our Phase 1b trial for ATR04 and pre-clinical studies of other product candidates and obtain regulatory approval or changes in regulatory framework that are out of our control; our estimation of addressable markets of our product candidates may be inaccurate; we may fail to timely raise additional required funding; more efficient competitors or more effective treatments for the diseases we target may become available; our product candidates may not be effective; there may be delays in regulatory approval or changes in regulatory framework that are out of our control; additional risks concerning effective competing treatment may emerge; we may be involved in disputes surrounding the use of our intellectual property and we are dependent on third-parties for some or all aspects of our product manufacturing, research and preclinical and clinical testing. Additional risks concerning Azitra’s programs and operations are described in its registration statement on Form S-1, which is on file with the SEC, and in its most recent annual report on Form 10-K to be filed with the SEC. Azitra explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.


Norman Staskey
Chief Financial Officer
nstaskey@azitrainc.com

Hayden RS
James Contracts
(973) 752-1421
hayden@haydenrs.com

Source: Azitra, Inc.